Viatris Agrees to Purchase Pacira BioSciences for 1.65 Billion Dollars

Advisers

Both corporations retained specialized investment banking and legal professionals to negotiate the transaction terms and navigate the regulatory review processes. According to the October 8, 2026, press release issued by Viatris, Morgan Stanley & Co. LLC acted as the primary financial advisor to the acquiring company. Centerview Partners LLC provided strategic and financial advice to Viatris management throughout the evaluation period. Cravath, Swaine & Moore LLP served as legal counsel to Viatris, handling the drafting of the definitive merger agreement and advising on regulatory compliance.

Pacira BioSciences engaged Goldman Sachs & Co. LLC to serve as its exclusive financial advisor during the sale process. Goldman Sachs rendered a fairness opinion regarding the cash consideration offered to the target company’s shareholders. Ashurst Perkins Coie acted as legal counsel for Pacira, representing the target board of directors in negotiations concerning the termination fee provisions, tender offer mechanics, and fiduciary out clauses.

How the transaction developed

The sequence of events leading to the acquisition announcement involves direct negotiations between the respective management teams. The public filings available on October 8, 2026, do not disclose the precise timeline of initial contact between Viatris and Pacira BioSciences. The regulatory disclosures and the SEC Form 8-K indicate that no competing bids were active at the time the definitive agreement was signed. The boards of directors for both companies approved the transaction unanimously before the market opening on October 8, 2026.

Pharmaceutical industry acquisitions of this magnitude typically follow months of private due diligence, assessing commercial contracts, patent portfolios, and regulatory compliance records. Viatris evaluated the Pacira non-opioid pain management portfolio to determine compatibility with its existing global distribution network. The absence of a financing contingency in the definitive agreement suggests Viatris completed its capital allocation planning well before finalizing the per-share purchase price. Following the announcement, Pacira shares traded upward by approximately 44 percent in premarket activity, while Viatris shares recorded a slight decline, according to Seeking Alpha on October 8, 2026.

Valuation metrics and financial comparables

The financial framework of the acquisition relies on revenue and earnings multiples derived from the target company’s trailing twelve-month performance. According to the SEC Form 8-K and the Viatris press release from October 8, 2026, Pacira generated approximately $746 million in revenue for the twelve months ended June 30, 2026. During the same period, the target company produced $177 million in adjusted EBITDA. The $1.65 billion aggregate equity value establishes an implied trailing equity-value-to-revenue multiple of approximately 2.21x.

The transaction yields an equity-value-to-adjusted-EBITDA multiple of approximately 9.32x based on the disclosed figures. The SEC Form 8-K filed on October 8, 2026, does not specify the target company’s exact enterprise value, omitting precise adjustments for assumed debt and acquired cash equivalents. Viatris management projected the transaction would be immediately accretive to the company’s financial guidance metrics, according to the official press release.

Comparable transactions within the pharmaceutical sector demonstrate similar valuation multiples for commercial-stage operators. Acquirers frequently pay between eight and twelve times adjusted EBITDA for specialized therapeutic manufacturers with established market penetration. The 44.8 percent premium paid by Viatris aligns with historical pharmaceutical industry averages for all-cash acquisitions involving single-asset or highly focused product portfolios. The valuation reflects the cash flow predictability associated with the target’s approved non-opioid therapeutics.

Acquisition structure and capital deployment

Viatris will execute the acquisition through a two-step transaction designed to accelerate the timeline to completion. According to the SEC Form 8-K filed on October 8, 2026, a wholly owned subsidiary of Viatris named Peach Purchaser Sub Inc. will initiate a first-step tender offer to acquire all outstanding common shares of Pacira BioSciences at the $36.50 offer price. Following the successful completion of the tender offer, the companies will execute a second-step merger under Section 251(h) of the Delaware General Corporation Law. This specific statutory provision eliminates the requirement for a separate shareholder meeting to approve the merger, provided the tender offer secures a majority of the outstanding shares.

The treatment of equity awards forms a specific component of the transaction structure. Outstanding restricted stock units and performance stock units will convert directly to cash at the $36.50 per share offer price upon the closing of the merger. Stock options held by Pacira employees with strike prices at or above the $36.50 consideration will be canceled without any cash payment, according to the SEC Form 8-K. This mechanism ensures all equity compensation instruments are resolved simultaneously with the transfer of control.

Viatris intends to fund the all-cash transaction using a combination of existing excess cash balances and short-term borrowing. The definitive agreement contains no financing contingency, obligating Viatris to complete the purchase regardless of broader credit market conditions. Viatris management expects the transaction to have a minimal impact on the company’s gross leverage ratio, according to the October 8, 2026, press release. The precise terms, borrowing facilities, and interest rate spreads associated with the short-term debt were not disclosed in the immediate regulatory filings.

Regulatory conditions and transaction timeline

The definitive agreement outlines specific milestones, regulatory approvals, and termination provisions that govern the closing process. The transaction must satisfy standard closing conditions before Peach Purchaser Sub Inc. can accept the tendered shares.

• October 8, 2026: Viatris and Pacira BioSciences execute the definitive merger agreement and announce the transaction to the public markets before the start of regular trading hours.
• October 29, 2026: Peach Purchaser Sub Inc. must commence the tender offer no later than 15 business days following the agreement date, according to the SEC Form 8-K.
• November 13, 2026: The initial tender offer period expires after 10 business days, though the purchaser retains the right to extend the offer under specific circumstances to achieve the minimum tender condition.
• December 31, 2026: The companies expect to close the transaction by year-end, pending the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• April 8, 2027: The merger agreement establishes an initial outside date for closing, beyond which either party may terminate the contract.
• July 8, 2027: The outside date extends automatically to this date if antitrust clearance remains the sole pending condition preventing the transaction from closing.

The agreement requires a minimum tender condition, mandating that shareholders validly tender at least one share more than 50 percent of Pacira’s outstanding common stock. The contract also includes a specific termination fee structure designed to compensate the acquirer if the transaction fails under certain scenarios. Pacira agreed to pay Viatris a termination fee of $62.0 million if the Pacira board accepts a “Superior Offer” from a competing bidder or makes an adverse recommendation change regarding the Viatris offer, according to the SEC Form 8-K.

Publisher consistency across regulatory filings and financial media

Financial journalists and regulatory documents present identical figures regarding the core economic terms of the acquisition. The SEC Form 8-K filed by Pacira BioSciences on October 8, 2026, confirms the $36.50 per share cash price and the $1.65 billion aggregate equity valuation. Reuters published a report on October 8, 2026, citing the identical $36.50 per share price, the $1.65 billion equity value, and the 44.8 percent premium calculation. Seeking Alpha reported the same financial parameters on October 8, 2026, noting the 44 percent premarket increase in the target’s stock price.

The uniformity across sources extends to the transaction structure and the projected timeline. The official Viatris press release, the SEC filings, and mainstream financial media all identify the end of 2026 as the target closing date. No publications report conflicting information regarding the termination fee, the equity conversion mechanics, or the financing arrangements. The enterprise value remains consistently absent across all primary documents and secondary reporting, as the acquiring company elected not to publish the specific debt assumption figures in the initial disclosure materials.

The transaction proceeds toward the commencement of the tender offer, pending the standard regulatory review by antitrust authorities and the subsequent decision by the target company’s institutional and retail shareholders.